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Functional characterization of cytokine autoantibodies in chronic renal
failure patients. We have recently reported on an increase of IL-i a and
IL-6 autoantibodies in patients maintained on chronic hemodialysis
treatment. The aim of the present study was to evaluate functional
properties of these autoantibodies. Serum samples of more then 500
chronic renal failure patients with and without replacement therapy
were screened for the presence of IL-la and IL-6 autoantibodies by
second antibody precipitation. The neutralizing capacity of IL-la
autoantibody serum was studied by immunofluorescence flow cytome-
try analysis of IL-la induced expression of E-selectin (ELAM-l,
CD62e) on HUVEC (human umbilical vein endothelial cells). Results of
these inhibition studies were confirmed with IgG preparations from
antibody positive sera, purified by affinity chromatography. Functional
studies on IL-6-dependent B9 cell proliferation were performed with
IL-6 autoantibody positive sera, and quantitated with the colorimetnc
MTT assay, IL-la induced expression of E-selectin on HUVEC (con-
sidered 100% positive cells) was inhibited by each IL-la autoantibody
positive serum sample (N = 13; anti-IL-la activity: 7.62 to 57.52%
binding). Inhibition of E-selectin expression by IL-Ia autoantibodies
ranged from 0.11 to 80.22% positive cells (0.15 to 92.31% mean
fluorescence intensity). A strong correlation of E-selectin expression
with IL-la autoantibody concentration was observed (P < 0.005).
Furthermore, IgG eluates from autoantibody positive patients inhibited
E-selectin expression to 41.0 23.1% positive cells if compared with
83.7 5.7% positive cells of the IgG depleted serum samples. IgG
eluates and IgG depleted sera derived from anti-IL-la negative serum
samples had no major influence on E-selectin expression (79.9 28.5%
and 77.9 16.8%, respectively). IL-6 autoantibody sera (N = 11;
anti-IL-6 activity: 5.85 to 53.28% binding) had no inhibitory effect on B9
cell proliferation (1:1000: 102.1 7.1%, 1:100: 106.8 9.2%, 1:10:
146.2 26.6% proliferation). We conclude that IL-la autoantibodies in
chronic renal failure patients deliver inhibitory activity on IL-la, at
least in vitro. IL-6 autoantibodies were not found to influence IL-6
dependent proliferation of B9 cells.
Recent work provides compelling evidence that naturally-
occurring cytokine antagonists are involved in regulatory mech-
anisms of the immune system [1—31. We have recently reported
on an increase of IL-i a and IL-6 autoantibodies in serum of
32.5% and 18.2% of hemodialysis patients, respectively [4, 5].
As the activity of IL-i and IL-6 is supposed to be increased in
hemodialysis patients [6—16], these autoantibodies might have
some influence on cytokine function in this clinical setting.
Furthermore, cytokine autoantibodies could be detected in
patients suffering from various other diseases such as septice-
mia [1, 17], rheumatoid arthritis [181, skin disorders [19, 20],
and even in some healthy subjects [17, 21, 22]. Since the
pathophysiological significance of cytokine autoantibodies is a
matter of debate, it was the aim of our study to evaluate the
functional properties of these autoantibodies.
Methods
Cytokine autoantibodies
Serum samples of more than 500 chronic renal failure patients
with and without replacement therapy were screened for the
presence of IL- 1 a and IL-6 autoantibodies as previously de-
scribed [4, 5, 18]. Following the addition of either 1251-IL-la or
'251-IL-6, autoantibody-bound '251-IL-1a11251-IL-6 was sepa-
rated by a second antibody immunoprecipitation followed by
centrifugation. Pellets were counted and results denoted as
percentage IgG-bound '251-IL-laI'251-IL-6 of total '251-IL-la/
'251..IL..6 activity. Reagents were from BUhlmann Lab AG
(Basel, Switzerland), and '251-IL-6 was obtained from Amer-
sham (Buckinghamshire, England). The cut off value for the
normal range of IL-la autoantibodies was 3.68% binding and
for IL-6 autoantibodies 2.87% binding [5].
Preparation of IgG eluates and IgG depleted sera
Serum samples of patients with high IL-la autoantibody
activity and autoantibody negative serum samples of healthy
subjects were loaded on a HiTrap Protein G affinity chromato-
graphy column (Pharmacia, Belgium). Bound IgG was eluted
with 0.1 M glycine HC1, the pH of the eluted fractions was
adjusted with 1 M Iris. Purity of eluted IgG was proven by
SDS-PAGE (Phast-Gel, Pharmacia, Belgium) and protein con-
centration was determined using the bicinchoninic acid method
(Micro BCA Protein Assay Reagent Kit, Pierce, USA).
Cell cultures
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Cell cultures of HUVEC (human umbilical vein endothelial
cells) were performed according to Jaffe et al as described
previously [23, 24]. Umbilical cord endothelial cells were
pooled and seeded on 35 mm culture wells (Costar, Cambridge,
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Massachusetts, USA) precoated with 1 mglcm2 fibronectin
(Sigma Chemical Co., St. Louis, Missouri, USA). Cells were
grown in RPMI-1640 containing 1% L-glutamine, 100 lU/mi
penicillin G, 100 mg/ml streptomycin, 5 mg/rn! fungizone,
supplemented with 5% fetal calf serum (FCS). Reaching con-
fluence within three to seven days, the average cell number per
well was about 5.5 0.7 x iO cells. Stimulation of E-selectin
(ELAM-l, CD62e) expression was achieved by incubating
HUVEC monolayers for four hours with rhulL-la at 10 U/ml
(5 x 108 U/mg; British Biotechnology, Oxford, UK) in 1 ml
medium [25].
B9 cells (provided by M. Schwabe, NC!, FCRDC, Frederik,
Maryland, USA) were maintained in RPMI-l640, supplemented
with 1% L-glutamine, penicillin G (100 lU/mi), streptomycin
(100 mg/mi), 10% heat-inactivated FCS and rhulL-6 (British
Biotechnology) at 50 pg/dl [26]. Culture media were from Gibco
(Grand Island, New York, USA).
Inhibition studies on IL-I a induced expression of E-selectin
on HUVEC
Neutralizing IL-la activity was tested by incubating IL-la
autoantibodies containing sera (final dilutions with medium
1:20, and in some experiments 1:200 and 1:500) either with
rhulL-la (10 U/mi) or with medium alone as control for one
hour at room temperature prior to coincubation with HUVEC.
The same protocol was run with IgG depleted serum samples
(final dilution 1:20) and with IgG eluates at a protein concen-
tration of 1 mg/mi. To confirm specificity, E-selectin expression
was inhibited by a monoclonal mouse anti-IL-i a antibody (data
not shown). Control experiments were performed with IL-i a
autoantibody negative uremic and normal donor serum samples
in 20-fold dilutions and with medium alone, as described above.
Cell viability of HUVEC previous to staining was more than
90% as determined by Trypan blue exclusion. After mild
collagenase detachment and two further washing steps, analysis
of surface molecule expression on HUVEC was performed by
flow cytometry analysis (FACScan, Becton Dickinson, Moun-
tain View, California, USA). Fifty microliter cell suspension
(S x i05 HUVEC/ml) was incubated with 50 ml of anti-E-
selectin mAb (4Db, Immunotech, Marseille, France; 30 mm at
room temperature), followed by staining with fluorescein la-
beled goat f(ab')2 anti-mouse IgG + 1gM antibody (30 mm at
4°C), fixation in 0.5% paraformaldehyde, and analyzing using
the LYSIS II software (Becton Dickinson).
Inhibition studies on IL-6 dependent proliferation of B9 cells
For the set up of the inhibition studies, B9 cells were washed
twice (in PBS, pH 7.2) to eliminate residual amounts of IL-6.
Viability (>90% in all experiments) was determined using
Trypan blue exclusion. One hundred microliter cell suspensions
per well (4 x iO B9 cells/p.l culture medium) were transferred
to a 96-well flat-bottomed culture plate (Costar) and incubated
with 100 p.I rhulL-6 (1 ng/ml) in serial 1:2 dilutions in medium as
positive control for 96 hours in quadruplicates (humidified air,
37°C, 5% C02). Inhibition of IL-6 activity with IL-6 autoanti-
body containing serum IL-6 autoantibody positive (N = 11) as
well as autoantibody negative uremic (N = 3) and normal
donors (N = 3) sera were incubated with rhulL-6, or medium
alone as control, for one hour at room temperature at a final 10-,
Table 1. Influence of IL-la autoantibody sera on E-selectin
expression on HUVEC
Patient
no.
IL-la autoantibody
% binding % Positive cells % mfi
1 57.52 0.1! 0.15
2 44.13 5.93 2.38
3 37.58 14.60 18.57
4 35.18 38.90 41.69
5 31.36 64.83 75.63
6 23.00 40.82 45.71
7 18.09 5.39 0.10
8 17.29 25.88 27.62
9 12.34 58.88 92.31
10 10.36 29.74 40.04
11 7.94 58.40 44.05
12 7.89 80.22 81,55
13 7.62 61.72 49.17
14 1.06 82.49 66.90
15 0.13 78.56 83.57
16 0.11 38.23 34.91
17 0.05 99.54 98.31
18 0.98 90.28 81.76
19 0.96 101.76 115.37
20 0.77 99.40 127.45
21 0.76 97.71 89.87
Patients 1 through 17 have chronic renal failure; 18 to 21 are healthy
subjects. Abbreviation mfl is mean fluorescence intensity.
100-, and 1000-fold dilution, prior to the proliferation assay.
One unit of IL-6 was defined as the concentration leading to half
maximal B9 cell proliferation (25 to 250 pg/mi). IL-6 specificity
of cell proliferation was confirmed by inhibition studies using a
mouse anti-IL-6 mAb.
Proliferation of B9 cells was determined with the MiT assay
[27]. MTT [3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
hum bromide, Sigma Chemical Co.] was dissolved in PBS (5
mg/mi = stock solution) and sterile filtered. This stock solution
was diluted 1:10 with medium and 25 j.d were added to each well
after discarding 125 ml of the supernatant. Plates were incu-
bated at 37°C. After four hours, 125 pJ of 0.04 N HC1 in
isopropanol were added to each well and plates were shaken to
dissolve MIT crystals. Within at least one hour, plates were
read on a micro-ELISA reader at a wavelength of 570 nm and a
reference wavelength of 620 nm. Results of the inhibition
studies are presented as percentage of IL-6 induced prolifera-
tion of B9 cells at the optimal IL-6 concentration.
Statistical analysis
Paired and unpaired data were calculated with Student's
t-test or Pearson's correlation coefficient; P < 0.05 was consid-
ered to be significant.
Results
IL-i a and IL-6 autoantibody positive sera
Serum samples from 13 IL-la and 11 IL-6 autoantibody
positive uremic donors, as well as antibody negative uremic and
normal donors' serum samples were selected for the inhibition
studies. IL-la and IL-6 autoantibody activities of the individual
serum samples are indicated in Tables 1 and 2.
Three further serum samples of IL-la autoantibody positive
patients and of three autoantibody negative healthy subjects
were depleted from IgG by affinity chromatography. Anti-IL-la
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Patient
no.
IL-6 autoantibody
%binding
Proliferation % OD
1:1000 1:100 1:100
1 53.28 101.1 97.3 125.5
2 29.64 117.1 119.0 113.3
3 17.55 106.3 117.1 108.2
4 15.25 95.8 120.4 192.3
5 12.84 101.8 101.8 148.1
6 7.27 105.4 109.4 162.3
7 7.18 88.4 95.0 119.3
8 7.14 105.8 97.2 146.7
9 7.07 102.5 109.8 162.5
10 6.10 98.4 107.4 159.0
11 5.85 100.9 100.6 170.6
12 0.81 106.2 115.4 280.0
13 0.10 97.5 102.1 112.6
14 0.10 95.1 207.7 209.2
15 0.16 100.2 98.6 95.5
16 0.10 92.4 108.0 106.1
17 0.01 87.7 135.4 406.2
activity of the antibody positive sera was 17.28, 36.21, and
57.82%, respectively. IL-i a autoantibody activity of the three
normal donor sera was <3.68% in each case.
Neutralizing activity of IL-i a autoantibody serum
Flow cytometry analysis of HUVEC was performed to quan-
titate anti-IL-la mediated inhibition of IL-la induced surface
expression of E-selectin. Following treatment with IL-la (10
UIml; 4 hr), cell populations weakly positive for E-selectin
gained a strong positive staining pattern. Percentage of E-
selectin positive cells and % mean fluorescence intensity (mfi)
was calculated as follows:
(sample — control): (IL-la — control) x 100.
Incubation of IL-i a with IL-i a autoantibody positive serum,
performed prior to coincubation with HUVEC, blocked E-
selectin expression strictly depending on antibody concentra-
tion and final dilution of serum samples (N = 13; 0.11 to 80.22%
positive cells, 0.10 to 92.31% mfi). Individual data are shown in
Table 1.
Serial serum dilutions up to 1:500 from one patient with
10.36% antibody activity abolished the inhibitory effect of
IL-la autoantibodies on E-seiectin expression completely (Fig.
1). In further experiments, normal (N 4) and uremic (N =4)
donors' sera which were negative for IL-la autoantibodies
showed no major influence on E-selectin expression in all but
one of the serum samples (90.28 to 101.76% positive cells, 81.76
to 127.45% mfi, and 38.23 to 99.54% positive cells, 66.9 to
98.31% mfi, respectively). The correlation of anti-IL-i a activity
and autoantibody mediated inhibition of E-selectin expression
was highly significant (N = 21, r 0.786, P < 0.005; Fig. 2).
Neutralizing activity of IgG depleted serum and purified IgG
IgG eluates from three IL- 1 a autoantibody positive and three
negative serum samples, isolated by affinity chromatography,
were adjusted to a protein concentration of 1 mg/mI. IgG eluates
from autoantibody positive serum samples inhibited IL-la
Medium IL-i 1/20 1/200 1/500
Fig. 1. Inhibition of E-selectin expression on HUVEC by serial dilu-
tions of IL-la autoantibody serum in one patient. Symbols are: ()
positive cells; () mfi. In this experiment 43.04% of HUVEC expressed
E-selectin following stimulation with IL-la (32.63% mfi). Incubation
with IL-la autoantibody serum (10.36% binding) resulted in a nearly
complete inhibition of E-selectin expression (8.93% positive cells,
10.32% mfi). Increasing dilutions of anti-IL-la serum up to 1:500 hardly
inhibited E-selectin expression (1:200: 34.82% positive cells, 26.77%
mfi; 1:500: 39.93% positive cells, 33.58% mfi).
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Fig. 2. Correlation of IL-I a autoantibody activity with expression of E-
selectin. Coincubation of HUVEC with IL-la autoantibody serum
resulted in an inhibition of IL-la induced expression of E-selectin. The
concentration of IL-la autoantibodies in individual serum samples(N = 21) correlated significantly with the decrease of E-selectin
expression (Y = —0.385x + 36.541, r = 0.786, P < 0.005).
induced expression of E-selectin in nearly the same manner as
untreated serum samples (41.01 23.1% and 30.3 13.5%
positive cells, respectively), whereas the IgG depleted serum
had no major influence on E-selectin expression (83.7 5.7%
positive cells). In anti-IL-la negative serum samples the corre-
sponding results were 79.9 28.5, 77.9 16.8, and 84.4
20.1% positive cells, respectively (Fig. 3).
Neutralizing activity of IL-6 autoantibodies
Using the colorimetric MTT-assay, IL-6 dependent prolifer-
ation of B9 cells was evaluated. Maximal proliferation was
observed at IL-6 concentrations of 25 to 250 pg/mi, and the
respective ODs in individual experiments were assigned as
100% proliferation (Table 2). Preincubation of IL-6 with serial
dilutions of anti-IL-6 autoantibody serum samples did not result
Table 2. Influence of IL-6 autoantibody sera on B9 cell proliferation
a)0)
C
a)0
a)
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Patients 1 through 14 have chronic renal failure; 15 to 17 are healthy
subjects.
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Fig. 3. Inhibition studies of E-selectin expression on HUVEC with IgG
eluates and IgG depleted sera of IL-la autoantibody positive () and
negative () sera. IL-la induced expression of E-selectin on HUVEC
is inhibited by crude serum and IgG eluates of IL-la autoantibody
positive sera, but not by IgG depleted positive sera or IL-la autoanti-
body negative serum samples, IgG eluates, or IgG depleted sera (N =
3 in each experiment).
in an autoantibody dependent abrogation of B9 cell proliferation
(N = 11; 1:1000: 102.1 7.1%; 1:100: 106.8 9.2% prolifera-
tion), as it was seen with the mouse IL-6 mAb. However,
incubation with a ten-fold serum dilution resulted in an unspe-
cific stimulation of B9 cell proliferation (146.2 26.6%, P <
0.05). IL-6 autoantibody negative normal (N =3)and uremic (N
= 3) donors' sera had no inhibitory activity on B9 cell prolifer-
ation (1:1000, 93.4 6.3% and 99.6 5.8%; 1:100, 114.0
19.1% and 141.7 57.6%, respectively), but stimulated prolif-
eration at a tenfold dilution (202.6 176.4% and 200.6 80.0%,
respectively) in some cases.
Discussion
IL-la and IL-6 autoantibodies can be detected with high
prevalence in hemodialysis patients, in contrast to other renal
failure patients or normal individuals [4, 5]. In the present
study, we focused our interest on putative functional properties
of these autoantibodies. Our results clearly demonstrate that
IL-i a autoantibodies, present in uremic serum, block the IL-i a
mediated expression of E-selectin on HUVEC, whereas IL-6
autoantibody sera failed to specifically inhibit IL-6 activity, at
least IL-6 induced proliferation of B9 cells.
Concerning other in vitro studies, some authors were able to
demonstrate an inhibitory effect of IL-i a autoantibodies on
IL-i a binding to its receptor on endothelial, synovial and T
cells, and on IL-i a dependent proliferation of thymocytes
[1, 18, 21]. Furthermore, endothelial adherence of neutrophils
could be blocked by anti-IL-i a IgG containing serum [28].
Additionally, tissue distribution and the rapid clearance of
exogeneous IL-la in rodents was heavily influenced by IL-la
autoantibodies [19, 201.
Little information exists regarding IL-6 autoantibodies.
Hansen described interference of polyclonal anti-IL-6 IgG,
derived from normal donors' sera, with recovery of exogeneous
IL-6 in an ELISA system. As demonstrated by gel filtration
techniques, these antibodies coprecipitated 1251-IL-6, and were
shown to bind predominantly to monomeric IL-6, and second
antibody precipitation indicated that more than one IgG mole-
cule bound to a single IL-6 molecule. Additionally, excess
amounts of unlabeled IL-6 completely displaced '251-IL-6 from
anti-IL-6 IgG [22].
Whether human cytokine autoantibodies have inhibitory
functions or facilitate transport and binding to specific target
sites in vivo, by protecting cytokines from urinary excretion,
proteolytic degradation or binding to other receptors, remains
to be elucidated. Bendtzen et al assumed that cytokine autoanti-
bodies might be encoded in germ-line genes, and get switched
on upon demand [1]. This assumption is strenghtened by the
observation of a very rapid occurrence of IL-i a and TNFa
autoantibodies in patients suffering from septicemia [1, 17].
In our study, IL-la induced expression of E-selectin on
HUVEC could nearly completely be blocked by uremic serum
containing IL-ia autoantibodies in a dose dependent manner.
Specificity of this phenomenon was proven by experiments
using IgG depleted serum as well as IgG eluates, isolated by
affinity chromatography. On the other hand, anti-IL-i a nega-
tive uremic and normal donors' sera and IgG eluates failed to
influence IL-i a induced expression of E-selectin on HUVEC in
most cases. These autoantibodies might protect some hemodi-
alysis patients from proinflammatory effects of IL-i, such as the
increase of leukocyte adherence to the vessel wall.
IL-6 autoantibodies in chronic renal failure patients sera did
not inhibit cytokine function in vitro. However, the failure of
IL-6 autoantibodies to block IL-6 dependent proliferation of B9
cells might be due to the presence of multimeric IL-6 molecules,
not completely neutralized by IL-6 autoantibodies [29]. Fur-
thermore, IL-6 autoantibodies might bind to IL-6 epitopes
distinct from the receptor binding part of the molecule. Addi-
tionally, the influence of different cytokine binding molecules,
such as soluble receptors or receptor antagonists on these assay
systems, cannot be ruled out [2, 301. Applying higher concen-
trations of anti-IL-6 positive and negative sera resulted in a
more pronounced proliferation of B9 cells in some experiments.
This was not unexpected and might, at least in part, be due to
an increased protein concentration, or a synergistic effect of
other cytokines, as it was recently demonstrated for IL-2 [31].
In summary, this study demonstrates the presence of a factor
in uremic serum, interfereing with the endothelial "adhesion
cascade" [32]. Our data confirm a neutralizing capacity of
IL-ia, but not of IL-6 autoantibodies, in chronic renal failure
patients maintained on hemodialysis treatment.
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